Anti-Fibrinolytic Drugs - LATAM

LATAM

Revenue in the Anti-Fibrinolytic Drugs market is projected to reach €0.63bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 4.46%, resulting in a market volume of €0.75bn by 2028.
In global comparison, most revenue will be generated in the United States (€9,141.00m in 2024).

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

A significant share of the Anti-Fibrinolytics market is dominated by only a small number of drugs, yet the revenue per drug is not as high as in many other markets. Throughout the time period considered, anti-fibrinolytics revenue shows steady growth. The negative impact of the COVID-19 pandemic, i.e., fewer new patients and canceled or postponed surgeries, is not reflected in the overall market figures because of the rollout of Roche's Hemlibra in 2020.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.